Table 1 Pre-COVID-19 summary of the patients’, underlying disease and HCT characteristics.
Number of patients | 91 (100%) |
Median Age upon COVID-19 infection | 35 years |
<18 | 15 (16%) |
18–40 | 32 (35%) |
>40 | 44 (48%) |
Sex | |
Female | 38 (42%) |
Male | 53 (58%) |
BMI | |
<30 | 66 (73%) |
>30 | 24 (26%) |
missing | 01 (01%) |
Comorbidity | |
None | 47 (52%) |
Active GvHD | 12 (13%) |
DM | 09 (10%) |
HTN | 06 (07%) |
Cardiovascular | 04 (04%) |
Pulmonary | 03 (03%) |
Other organs dysfunction | 10 (11%) |
Multiple comorbidities | 15 (16%) |
Hematological or underlying disease | |
Benign | 21 (23%) |
Leukemia | 27 (30%) |
Lymphoma | 26 (29%) |
Myeloma | 16 (18%) |
Solid tumors | 01 (01%) |
Stem cell Transplant type | |
Allogeneic | 52 (57%) |
Autologous | 39 (43%) |
Number of transplants | |
One | 81 (89%) |
Two | 10 (11%) |
Conditioning intensity | |
MAC | 81 (89%) |
RIC | 10 (11%) |
Conditioning type | |
TBI | 20 (22%) |
Non-TBI | 70 (77%) |
Missing | 01 (01%) |
Median time from HCT to COVID-19 | 14.9 (IQR: 16.3 to 38.9) months |
<6 months | 23 (25%) |
6–12 months | 15 (16%) |
>12 months | 53 (59%) |
Prophylactic antimicrobials before COVID-19 | |
Antiviral | 23 (25%) |
Antibacterial | 04 (04%) |
Both | 37 (41%) |
None | 27 (30%) |
Immunosuppressant upon COVID-19 | |
No | 42 (46%) |
Yes | 47 (52%) |
Missing | 02 (02%) |
Disease status | |
Active | 03 (03%) |
In remission or not applicable (benign or solid tumors) | 88 (97%) |
